In the present study, we successfully introduced the T315I (ACT to ATT) mutation of the BCR::ABL1 fusion gene and the T125M (ACG to ATG) mutation of the TP53 gene into human leukemia cell lines by utilizing the CBE system and evaluated their significance in the drug sensitivities. This evidence concerns the gene BCR and leukemia.